The ADC drug "Dabigatran Etexilate" from Daiichi Sankyo/Astrazeneca PLC Sponsored ADR (AZN.US) has received approval for another new indication in China.
On August 12, Daiichi Sankyo announced that a new indication for its blockbuster ADC drug "Enhertu," developed in collaboration with AstraZeneca, has been approved for marketing.
On August 12, Daiichi Sankyo announced that a new indication for its blockbuster ADC drug "trastuzumab deruxtecan" developed in collaboration with AstraZeneca has been approved for launch. The indication is for use in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
Trastuzumab deruxtecan (DS-8201, brand name: Enhertu) is a HER2-targeting ADC drug developed by Daiichi Sankyo, in collaboration with AstraZeneca for global development and commercialization. The drug consists of a HER2-targeting antibody, a cleavable tetrapeptide linker, and a topoisomerase I inhibitor DXd (derivative of irinotecan), with a DAR of approximately 8.
Related Articles
US Stock Market Move | In the first half of the year, losses surged, and XPeng Group (XPEV.US) fell by nearly 7%.
US Stock Market Move | The core executives have stepped in to increase their holdings as the decline in Alibaba Group Holding Limited Sponsored ADR (BABA.US) has narrowed to 0.23%.
CNGR Advanced Material (02579) announced its mid-term results, with a profit attributable to the owners of the parent company of approximately 1.3114 billion yuan, an increase of about 78.4% year-on-year.
US Stock Market Move | In the first half of the year, losses surged, and XPeng Group (XPEV.US) fell by nearly 7%.
US Stock Market Move | The core executives have stepped in to increase their holdings as the decline in Alibaba Group Holding Limited Sponsored ADR (BABA.US) has narrowed to 0.23%.
CNGR Advanced Material (02579) announced its mid-term results, with a profit attributable to the owners of the parent company of approximately 1.3114 billion yuan, an increase of about 78.4% year-on-year.
RECOMMEND
